perspectives in aortic treatment cytosorb · pdf file3rd aortic live symposium perspectives in...
TRANSCRIPT
![Page 1: PERSPECTIVES IN AORTIC TREATMENT CYTOSORB · PDF file3rd aortic live symposium perspectives in aortic treatment cytosorb therapy: controlling the hyperinflammation during and post](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9d48b67f8b9abd058b6a71/html5/thumbnails/1.jpg)
3rd Aortic Live Symposium
PERSPECTIVES IN AORTIC TREATMENT
CYTOSORB THERAPY:
CONTROLLING THE
HYPERINFLAMMATION DURING AND POST
CPB
PROF. DR. KARL TRÄGERCARDIOSURGICAL ICU
DEPT. OF CARDIAC ANESTHESIOLOGYUNIVERSITY HOSPITAL ULM
ALBERT-EINSTEIN-ALLEE 23, 89081 ULMGERMANY
![Page 2: PERSPECTIVES IN AORTIC TREATMENT CYTOSORB · PDF file3rd aortic live symposium perspectives in aortic treatment cytosorb therapy: controlling the hyperinflammation during and post](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9d48b67f8b9abd058b6a71/html5/thumbnails/2.jpg)
Disclosure
2
Speaker name:
.....................Dr. Karl Traeger.........................................................
I have the following potential conflicts of interest to report:
Consulting
Employment in industry
Stockholder of a healthcare company
Owner of a healthcare company
Other(s)
I do not have any potential conflict of interest
No surgical skills Intensivist
![Page 3: PERSPECTIVES IN AORTIC TREATMENT CYTOSORB · PDF file3rd aortic live symposium perspectives in aortic treatment cytosorb therapy: controlling the hyperinflammation during and post](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9d48b67f8b9abd058b6a71/html5/thumbnails/3.jpg)
Cardio-Pulmonary-Bypass (CPB) as a
paradigm of an inflammatory insult
3
Time (days / weeks)
Pro-Inflammation Anti-Inflammation
Organ failure
death
recovery
TOXIC
![Page 4: PERSPECTIVES IN AORTIC TREATMENT CYTOSORB · PDF file3rd aortic live symposium perspectives in aortic treatment cytosorb therapy: controlling the hyperinflammation during and post](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9d48b67f8b9abd058b6a71/html5/thumbnails/4.jpg)
Pathophysiology of sepsis
NEJM (2013) 369:840
4
Proinflammatory response
Excessive Inflammation causing collateral damage (tissue injury)
![Page 5: PERSPECTIVES IN AORTIC TREATMENT CYTOSORB · PDF file3rd aortic live symposium perspectives in aortic treatment cytosorb therapy: controlling the hyperinflammation during and post](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9d48b67f8b9abd058b6a71/html5/thumbnails/5.jpg)
Interleukin-6 in sepsis and capillary leakage syndromeKrüttgen A et al.: J Interferon Cytokine Res 2012, 32:60
5
• … Thus, vascular leakage caused by IL-6 transsignaling (resulting in tissue edema and hypoxia) represents a valuable novel target for pharmaceutical intervention and basic
science …
Capillary leakage > tissue edema > hypoxia > necrosis
![Page 6: PERSPECTIVES IN AORTIC TREATMENT CYTOSORB · PDF file3rd aortic live symposium perspectives in aortic treatment cytosorb therapy: controlling the hyperinflammation during and post](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9d48b67f8b9abd058b6a71/html5/thumbnails/6.jpg)
Overwhelming SIRS post CPBSIRS - the systemic inflammatory response syndrome after cardiac operations
Taylor KM, Ann Thorac Surg 1996, 61:1607
6
• Therapeutic approaches
• MECC (minimalized
extracorporeal circulation)
• Hemofiltration during CPB
• Steroids
• Catecholamines
• Vasopressin
• Hemoadsorption
• Clinical symptoms
– Hypotension
– Vasoplegia
– Capillary leakage
– Pulmonary
Dysfunction
– Renal Dysfunction
– MODS
• Pathophysiology
– Inflammatory
stimuli
– Surface contact
– Inflammatory
cytokine release
– DAMPs
![Page 7: PERSPECTIVES IN AORTIC TREATMENT CYTOSORB · PDF file3rd aortic live symposium perspectives in aortic treatment cytosorb therapy: controlling the hyperinflammation during and post](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9d48b67f8b9abd058b6a71/html5/thumbnails/7.jpg)
Strategies to manage overwhelming SIRS post CPB
7
• Prophylaxis
• Preemptive treatment
• Treatment (ICU)– Catecholamines
– Steroids
– Vasopressin
– Fluids
– Organ support therapy
• Cytokine eliminationCytokines in the systemic inflammatory response
syndrome: a review
Jaffer U et al: HSR Proc Intensive Care Cardiovasc Anesth
2010, 2:161
![Page 8: PERSPECTIVES IN AORTIC TREATMENT CYTOSORB · PDF file3rd aortic live symposium perspectives in aortic treatment cytosorb therapy: controlling the hyperinflammation during and post](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9d48b67f8b9abd058b6a71/html5/thumbnails/8.jpg)
EFFICACY– Effective in decreasing elevated cytokine levels
CE REGISTRATION (EUROPE)– First registered cytokine adsorber in Europe
SAFETY– Safety by high biocompatibility (ISO 10993)
SIMPLE USE– Simple integration in CRRT circuits– Whole blood hemoperfusion
FAST SETUP AND EASY HANDLING– Compatibility with standard CRRT devices
REIMBURSEMENT– OPS-Code 8-856, ZE 2014-09
Controlling cytokine storm during SIRS and
SEPSIS by ADSORPTION (CytoSorb)
8
![Page 9: PERSPECTIVES IN AORTIC TREATMENT CYTOSORB · PDF file3rd aortic live symposium perspectives in aortic treatment cytosorb therapy: controlling the hyperinflammation during and post](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9d48b67f8b9abd058b6a71/html5/thumbnails/9.jpg)
Polymer-Technology:
Bead Adsorber (Polystyrene-divinyl-copolymer)
9
Blutfluss
• 300ml cartridge with „Bead“ design
• HighTech-Polymer
• Size selectivity < 55kD
• Low flow resistance
• 120ml volume
• Prefilled with NaCl solution
• Gamma sterilized, 3 yrs storable
![Page 10: PERSPECTIVES IN AORTIC TREATMENT CYTOSORB · PDF file3rd aortic live symposium perspectives in aortic treatment cytosorb therapy: controlling the hyperinflammation during and post](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9d48b67f8b9abd058b6a71/html5/thumbnails/10.jpg)
Configuration and structureValenti, I “Characterization of a Novel Sorbent Polymer for the
Treatment of Sepsis” 2008
10
CytoSorb™ Beads Electron microscopic view of internal
structure
![Page 11: PERSPECTIVES IN AORTIC TREATMENT CYTOSORB · PDF file3rd aortic live symposium perspectives in aortic treatment cytosorb therapy: controlling the hyperinflammation during and post](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9d48b67f8b9abd058b6a71/html5/thumbnails/11.jpg)
Adsorber surface
11
Membrane filter CytoSorb® Absorber
>40.000qmca. 2 qm
![Page 12: PERSPECTIVES IN AORTIC TREATMENT CYTOSORB · PDF file3rd aortic live symposium perspectives in aortic treatment cytosorb therapy: controlling the hyperinflammation during and post](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9d48b67f8b9abd058b6a71/html5/thumbnails/12.jpg)
Controlling cytokine storm in the
cardiosurgical patient
13
Preemptive approach
• During CPB
Therapeutic approach
• Adjunctive therapy
postoperative / ICU
![Page 13: PERSPECTIVES IN AORTIC TREATMENT CYTOSORB · PDF file3rd aortic live symposium perspectives in aortic treatment cytosorb therapy: controlling the hyperinflammation during and post](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9d48b67f8b9abd058b6a71/html5/thumbnails/13.jpg)
CytoSorb Treatment in
14
SIRS post CPB
![Page 14: PERSPECTIVES IN AORTIC TREATMENT CYTOSORB · PDF file3rd aortic live symposium perspectives in aortic treatment cytosorb therapy: controlling the hyperinflammation during and post](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9d48b67f8b9abd058b6a71/html5/thumbnails/14.jpg)
Treatment of post-cardiopulmonary bypass SIRS by
hemoadsorption: a case seriesTräger K et al., Int J Artif Organs 2016; 39: 141
15
IL-6 levels
IL-8 levels
![Page 15: PERSPECTIVES IN AORTIC TREATMENT CYTOSORB · PDF file3rd aortic live symposium perspectives in aortic treatment cytosorb therapy: controlling the hyperinflammation during and post](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9d48b67f8b9abd058b6a71/html5/thumbnails/15.jpg)
CytoSorb Treatment in
16
SIRS post CPB
![Page 16: PERSPECTIVES IN AORTIC TREATMENT CYTOSORB · PDF file3rd aortic live symposium perspectives in aortic treatment cytosorb therapy: controlling the hyperinflammation during and post](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9d48b67f8b9abd058b6a71/html5/thumbnails/16.jpg)
Treatment of post-cardiopulmonary bypass SIRS by
hemoadsorption: a case seriesTräger K et al., Int J Artif Organs 2016; 39: 141
17
Epinephrine
Norepinephrine
Cardiac index
MAP
![Page 17: PERSPECTIVES IN AORTIC TREATMENT CYTOSORB · PDF file3rd aortic live symposium perspectives in aortic treatment cytosorb therapy: controlling the hyperinflammation during and post](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9d48b67f8b9abd058b6a71/html5/thumbnails/17.jpg)
Treatment of post-cardiopulmonary bypass SIRS by
hemoadsorption: a case seriesTräger K et al., Int J Artif Organs 2016; 39: 141
18
Base excess
Lactate
![Page 18: PERSPECTIVES IN AORTIC TREATMENT CYTOSORB · PDF file3rd aortic live symposium perspectives in aortic treatment cytosorb therapy: controlling the hyperinflammation during and post](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9d48b67f8b9abd058b6a71/html5/thumbnails/18.jpg)
Adsorptive blood purification for control of
inflammation triggered organ dysfunction
19
Effects of hemadsorption with CytoSorb
in postoperative severe SIRS und Sepsis
• Reduction of increased cytokine levels
• Positive hemodynamic effects
• Reduced catecholamine need
• Metabolic stabilization
![Page 19: PERSPECTIVES IN AORTIC TREATMENT CYTOSORB · PDF file3rd aortic live symposium perspectives in aortic treatment cytosorb therapy: controlling the hyperinflammation during and post](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9d48b67f8b9abd058b6a71/html5/thumbnails/19.jpg)
Controlling cytokine storm in the
cardiosurgical patient
20
Preemptive approach
• During CPB
![Page 20: PERSPECTIVES IN AORTIC TREATMENT CYTOSORB · PDF file3rd aortic live symposium perspectives in aortic treatment cytosorb therapy: controlling the hyperinflammation during and post](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9d48b67f8b9abd058b6a71/html5/thumbnails/20.jpg)
„Collateral“ elimination effects with
CytoSorb treatment
21
Elimination of
– Free hemoglobin
Dimer 32 kDa
Tetramer 65 kDa
– Myoglobin 17 kDa
– Bilirubin 8 kDa
– Toxins
– ?
![Page 21: PERSPECTIVES IN AORTIC TREATMENT CYTOSORB · PDF file3rd aortic live symposium perspectives in aortic treatment cytosorb therapy: controlling the hyperinflammation during and post](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9d48b67f8b9abd058b6a71/html5/thumbnails/21.jpg)
– SIRS post CPB
– Septic schock
– Severe
reperfusion
– Severe hemolysis
– …
CONCLUSIONCytoSorb treatment options in cardiac surgery
22
– Acute endocarditis
– Local infections
– Complex and long
lasting surgery
– Long CPB and
x-clamp time
– Re-Do
– …
![Page 22: PERSPECTIVES IN AORTIC TREATMENT CYTOSORB · PDF file3rd aortic live symposium perspectives in aortic treatment cytosorb therapy: controlling the hyperinflammation during and post](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9d48b67f8b9abd058b6a71/html5/thumbnails/22.jpg)
Koordination:
ZKS, Zentrum für Klinische Studien am Universitätsklinikum Jena(Prof. Dr. F.M. Brunkhorst)
CytoSorb Registry
http://www.cytosorb-registry.org
23
![Page 23: PERSPECTIVES IN AORTIC TREATMENT CYTOSORB · PDF file3rd aortic live symposium perspectives in aortic treatment cytosorb therapy: controlling the hyperinflammation during and post](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9d48b67f8b9abd058b6a71/html5/thumbnails/23.jpg)
Future perspective: CytoSorb treatment in cardiac surgery and
intensive care medicine…